Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D00YWL
|
|||
Former ID |
DIB001371
|
|||
Drug Name |
BMS-936557
|
|||
Synonyms |
Anti-CXCL10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Medarex/BMS; Anti-IP-10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Bristol-Myers Squibb/Medarex
Click to Show/Hide
|
|||
Drug Type |
Antibody
|
|||
Indication | Immune System disease [ICD-11: 4A01-4B41; ICD-10: D80-D89] | Phase 2 | [1] | |
Company |
Medarex Inc
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | C-X-C motif chemokine 10 (CXCL10) | Target Info | . | [2] |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
Chemokine signaling pathway | ||||
Toll-like receptor signaling pathway | ||||
RIG-I-like receptor signaling pathway | ||||
Cytosolic DNA-sensing pathway | ||||
TNF signaling pathway | ||||
Influenza A | ||||
NetPath Pathway | IL-7 Signaling Pathway | |||
TSLP Signaling Pathway | ||||
TNFalpha Signaling Pathway | ||||
TWEAK Signaling Pathway | ||||
TCR Signaling Pathway | ||||
Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
Pathway Interaction Database | CXCR3-mediated signaling events | |||
Reactome | Chemokine receptors bind chemokines | |||
G alpha (i) signalling events | ||||
WikiPathways | Toll-like receptor signaling pathway | |||
Type II interferon signaling (IFNG) | ||||
Spinal Cord Injury | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
Regulation of toll-like receptor signaling pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01466374) Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease. U.S. National Institutes of Health. | |||
REF 2 | Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar;63(3):442-50. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.